Thus, effectively inhibiting BRCC3 expression in order to cause an insufficiency of homology-directed repair in glioma cells is a potential therapeutic strategy for sensitizing glioma tumor cells to the alkylating anti-tumor drugs. This evidence concerns the gene BRCC3 and glioma.